MEDBOT-B (02252) has announced that as of the date of this announcement, global commercial orders for its core product, the Toumai® laparoscopic surgical robot, have exceeded 200 units. The system is now deployed in nearly 50 countries and regions, with close to 130 units already installed for commercial use.

This new milestone in the volume of Toumai's commercial orders and installations signifies its ongoing and widespread clinical acceptance worldwide. It serves as a systematic validation of the robot's safety, stability, and reliability. Surgeons from various countries, healthcare systems, and surgical specialties are increasingly integrating Toumai into their daily surgical practices and long-term departmental development, based on practical and careful clinical decisions.

Among the nearly 50 countries and regions where Toumai is present, 12 have placed orders for more than 5 units. Growth is particularly strong in emerging markets such as India, Brazil, and Argentina, with cumulative orders reaching 14 units in India and over 10 in Brazil. The system continues to make inroads in developed markets as well, with countries like Spain and Australia becoming key areas of rapid growth. Toumai's commercialization has established a new pattern of multi-regional synergy, spanning both emerging markets in developing nations and mature healthcare systems in developed countries.

While its global expansion accelerates, Toumai is also achieving breakthroughs in the depth of clinical application within individual medical centers. According to internal data, dozens of healthcare institutions that have commercially installed the system have each performed over one hundred procedures. These operations span a wide range of specialties, including urology, general surgery, thoracic surgery, gynecology, pediatric surgery, and head and neck surgery.

As the world's first remote surgical robot system approved for commercial use, the Toumai remote surgical robot has received market authorization in nearly 10 countries, including China, India, and Brazil. Its applications now cover regions inhabited by nearly half of the global population, and it has pioneered the transition to routine, large-scale clinical use. To date, Toumai has successfully completed close to 800 remote surgeries across more than 20 countries, maintaining a 100% success rate.